预约演示
更新于：2026-02-27
Insulin detemir
地特胰岛素
更新于：2026-02-27
概要
基本信息
原研机构 |
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 欧盟 (2004-06-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
Sequence Code 4857
来源: *****
Sequence Code 91440
来源: *****
关联
191
项与 地特胰岛素 相关的临床试验ChiCTR2400080751
Study on the effect and mechanism of semaglutide in alleviating diabetic renal damage
NCT05124457
A Phase 2 Open Label Randomized Controlled Trial Determir Vs Neutral Protamine Hagedorn (NPH) In Pregnant Women: DETERMINE Study
NCT05134987
A Multiple Dose Study Investigating Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0363-0845 in Participants With Type 1 Diabetes
100 项与 地特胰岛素 相关的临床结果
登录后查看更多信息
100 项与 地特胰岛素 相关的转化医学
登录后查看更多信息
100 项与 地特胰岛素 相关的专利（医药）
登录后查看更多信息
959
项与 地特胰岛素 相关的文献（医药）2026-02-01AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
Diabetes in pregnancy and major new advances in diabetes care using long-acting and ultralong-acting insulins
Review
作者: Seif, Karl E ; Higgs, Arielle J ; Reece, E Albert ; Drummond, Rosa F
Pregestational diabetes complicates 1% to 2% of all pregnancies. Achievement of euglycemia prevents adverse maternal, fetal, and neonatal outcomes. Insulin is the first line and the backbone of diabetes treatment in and out of pregnancy, but the delicate balance between stringent control and hypoglycemia, along with the complexity and interruption of multiple injections per day, continues to make glycemic control challenging. The ideal basal insulin has a flat pharmacodynamic profile with minimal variability and is relatively easy for patients and clinicians to use. Insulin analogs, such as insulins glargine and detemir, are the most common basal insulins used in pregnancy at this time, but insulin degludec, which has advantages like prolonged duration of action in the nonpregnant population, was recently shown to be equally as effective as detemir in pregnancy. The ease of a once-daily injection without an increased risk of hypoglycemia is attractive to patients and clinicians who wish to simplify insulin regimens. Furthermore, there are current clinical trials evaluating once-weekly basal insulin regimens in the general population. This would decrease basal injections from a minimum of 365 per year to 52 per year, potentially increasing adherence and improving glycemic control. This review will discuss the evidence for insulin degludec in pregnancy as well as discuss the potential benefits and drawbacks of once-weekly ultralong-acting basal insulins in pregnancy.
2026-01-01ANNALS OF PHARMACOTHERAPY
Comparative Efficacy and Safety of Basal/Correctional Vs Basal/Bolus/Correctional Insulin Regimens in Medical Intensive Care Unit Patients Receiving Continuous Enteral Nutrition
Article
作者: Briscoe, Jessica ; Cohen, Aaron ; Van Berkel Patel, Megan ; Greenberg, Jeremy ; Caldwell, Lauren ; Parker, Jessica ; Stowe, Alicia
Background::
While glycemic control is essential in critically ill patients, the optimal insulin regimen for patients receiving continuous enteral nutrition (CEN) is unknown.
Objective::
This study compares glycemic control in basal/correctional vs basal/bolus/correctional insulin regimens in intensive care unit (ICU) patients receiving CEN.
Methods::
This retrospective study included patients ≥18 years old, admitted to the medical critical care service with administration of CEN and ≥20 units of insulin detemir daily for ≥48 hours. Patients receiving non-insulin hypoglycemic agents were excluded. The primary outcome was the comparison of glycemic control, assessed by mean blood glucose and percent of glucose checks in target range. Secondary outcomes included the comparison of hypoglycemia, hyperglycemic emergencies, and glycemic variability between groups.
Results::
A total of 100 patients were included, with 50 patients per group. Mean blood glucose and percent of blood glucose checks in the target range were similar between basal/correctional and basal/bolus/correctional groups (204.2 vs 194.2 mg/dL,
P
= 0.2433 and 37.8% vs 43.1%,
P
= 0.3182, respectively). There were no differences in hypoglycemia or hyperglycemic emergencies. Among patients receiving ≥60 units of insulin daily, the basal/bolus/correctional regimen was associated with lower mean blood glucose (197.1 vs 248.5 mg/dL,
P
< 0.0001) and increased glucose checks in target range (43.5% vs 9.1%,
P
= 0.0040) without increased hypoglycemia.
Conclusion and Relevance::
Among ICU patients requiring ≥20 units of insulin detemir daily while receiving CEN, basal/correctional and basal/bolus/correctional insulin regimens appear to offer similar glycemic control, but basal/bolus/correctional regimens may improve glycemic control in patients requiring ≥60 units of insulin daily.
2025-12-31JOURNAL OF MEDICAL ECONOMICS
Cost-effectiveness of insulin icodec for the treatment of type 2 diabetes in Canada
Article
作者: Mau, Godfrey ; Garcia, David A. ; Singh, Sumeet ; Spence, Michaela ; Goldenberg, Ronald ; Jensen, Morten Sall
AIM:
Patients with type 2 diabetes (T2D) with poor glycemic control despite use of non-insulin agents can experience delay in initiating insulin therapy and poor adherence to insulin therapy, predominantly due to the burden of multiple injections1-3. This study aimed to determine the cost-effectiveness of insulin icodec, first once-weekly basal insulin, compared with long-acting basal insulins for improving glycemic control in adults with T2D in Canada.
MATERIALS AND METHODS:
The Swedish Institute of Health Economics T2D Cohort Model was used to analyse three T2D groups: insulin naïve (IN), basal insulin experienced (BIE), and basal-bolus insulin experienced (BBIE). Comparators included insulin glargine, insulin detemir, and insulin degludec. Comparative efficacy was informed by the phase 3 ONWARDS trials of insulin icodec and network meta-analyses (NMA). Time horizon was 40 years. Analyses considered disutilities resulting from vascular complications, age, gender, diabetes duration, hypoglycemia, and injection burden. A 1.5% annual discount rate was used for costs and effects. The average cost per unit for each treatment, accounting for the market share of available formats and biosimilars was calculated. Outcomes were expressed as quality-adjusted life-years (QALYs) and cost-effectiveness as incremental cost utility ratios (ICUR [cost/QALY]).
RESULTS:
In all analyses, insulin icodec dominated insulin degludec and insulin detemir. Compared to insulin glargine U100 and U300, insulin icodec was associated with ICURs of $17,876, $20,844, and $73,253; and $6,439, $8,623, and $45,433 in the IN, BIE, and BBIE populations, respectively.
LIMITATIONS:
Limitations of this economic evaluation include the lack of data for some treatments in certain NMAs, uncertainty regarding the use of the NMA results for a 40-year time horizon, heterogeneous sources of disutilities, and uncertainty regarding the HRQoL benefits of reduced injection frequency.
CONCLUSIONS:
Insulin icodec is a cost-effective treatment option for adult patients with T2D versus once daily basal insulin-analogues publicly reimbursed in Canada.
100 项与 地特胰岛素 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 1型糖尿病 | 美国 | 2005-10-19 | |
| 2型糖尿病 | 美国 | 2005-10-19 | |
| 糖尿病 | 欧盟 | 2004-06-01 | |
| 糖尿病 | 冰岛 | 2004-06-01 | |
| 糖尿病 | 列支敦士登 | 2004-06-01 | |
| 糖尿病 | 挪威 | 2004-06-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 囊性纤维化相关糖尿病 | 临床3期 | 美国 | 2008-08-01 | |
| 肥胖 | 临床3期 | 西班牙 | 2005-04-01 | |
| 低血糖 | 临床3期 | 澳大利亚 | 2001-09-01 | |
| 低血糖 | 临床3期 | 克罗地亚 | 2001-09-01 | |
| 低血糖 | 临床3期 | 丹麦 | 2001-09-01 | |
| 低血糖 | 临床3期 | 意大利 | 2001-09-01 | |
| 低血糖 | 临床3期 | 南非 | 2001-09-01 | |
| 低血糖 | 临床3期 | 瑞典 | 2001-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 30 | insulin+detemir (Standard Insulin Drip Therapy) | 窪願糧窪積醖觸網網憲 = 糧襯繭繭鹽簾遞夢廠膚 壓夢製獵鏇鹽獵襯餘窪 (獵蓋壓願繭簾積艱選積, 淵壓鑰壓襯壓襯鹽鬱窪 ~ 積餘鬱糧獵夢鹹築襯憲) 更多 | - | 2021-12-07 | ||
(Insulin Drip and Detemir) | 窪願糧窪積醖觸網網憲 = 簾獵積願構獵選構艱鑰 壓夢製獵鏇鹽獵襯餘窪 (獵蓋壓願繭簾積艱選積, 鬱膚鬱網獵繭鑰淵廠選 ~ 蓋鹹鑰繭廠鏇壓壓網選) 更多 | ||||||
临床4期 | 108 | (Detemir) | 襯衊鹹蓋鹽淵襯窪窪淵 = 選窪壓壓壓憲夢築鬱壓 簾衊蓋鏇遞鏇夢範繭選 (範糧鹹窪壓衊簾膚襯網, 繭淵顧衊獵顧鹹鹹積膚 ~ 鑰繭鏇膚製窪積遞廠淵) 更多 | - | 2021-08-18 | ||
(Neutral Protamine Hagedorn (NPH)) | 襯衊鹹蓋鹽淵襯窪窪淵 = 構鏇廠顧蓋艱鬱淵簾鑰 簾衊蓋鏇遞鏇夢範繭選 (範糧鹹窪壓衊簾膚襯網, 壓選餘鑰憲淵艱鑰襯願 ~ 鹽鹽鹹鹹齋醖夢蓋鬱鏇) 更多 | ||||||
N/A | 2,446 | 遞壓鹹觸遞窪構獵憲製(膚鹽醖鏇遞鹽廠觸觸夢) = 範憲構顧艱鬱憲壓鏇簾 醖醖願衊廠憲鹹壓憲廠 (選壓遞廠構醖廠壓壓淵 ) 更多 | - | 2021-07-30 | |||
Other Basal Insulins | 遞壓鹹觸遞窪構獵憲製(膚鹽醖鏇遞鹽廠觸觸夢) = 繭蓋廠鬱簾鬱簾齋齋壓 醖醖願衊廠憲鹹壓憲廠 (選壓遞廠構醖廠壓壓淵 ) 更多 | ||||||
N/A | 22 | 網窪簾憲淵製顧繭壓壓(衊餘餘製範淵醖鬱齋齋) = 鏇簾繭遞齋淵鏇艱網鏇 網膚網範鬱遞艱艱艱餘 (壓蓋襯鹹構齋壓淵衊鏇, 鏇構窪積衊窪壓築遞衊 ~ 獵鬱餘鏇遞齋鏇蓋鑰積) 更多 | - | 2020-11-10 | |||
SGLT2i (Control Group) | 網窪簾憲淵製顧繭壓壓(衊餘餘製範淵醖鬱齋齋) = 襯齋淵觸衊獵蓋繭襯構 網膚網範鬱遞艱艱艱餘 (壓蓋襯鹹構齋壓淵衊鏇, 繭齋鹹願網積鹹壓網窪 ~ 遞艱鏇糧鏇窪餘醖觸獵) 更多 | ||||||
N/A | - | Insulin Detemir (IDet) | 築夢蓋獵積糧構繭構遞(積觸觸積廠醖積膚餘網) = 淵壓蓋顧範齋獵夢願鬱 糧範糧願淵簾鬱鬱積遞 (鹹糧齋願艱衊構廠餘衊 ) 更多 | 积极 | 2020-09-23 | ||
临床4期 | 157 | (Control: Metformin, Insulin Detemir, Insulin Aspart) | 鑰繭鬱獵鏇選觸壓鏇鹽(獵顧鑰窪夢遞膚鹽窪範) = 艱鏇餘鹹觸製蓋鹽壓壓 鹹獵夢餘遞憲襯範鬱齋 (遞廠廠願壓簾窪鹹製選, 艱壓築顧壓襯積窪齋膚 ~ 積觸構鏇鬱鑰蓋膚觸壓) 更多 | - | 2019-10-22 | ||
(Metformin, Insulin Determir, Liraglutide) | 鑰繭鬱獵鏇選觸壓鏇鹽(獵顧鑰窪夢遞膚鹽窪範) = 窪淵窪衊鹹鑰壓願選夢 鹹獵夢餘遞憲襯範鬱齋 (遞廠廠願壓簾窪鹹製選, 簾範醖餘窪憲醖鏇願鬱 ~ 壓觸遞醖獵廠衊顧簾憲) 更多 | ||||||
N/A | 33 | (Detemir) | 憲築鬱衊壓鑰遞繭鑰衊(壓積鏇鑰艱製艱鏇膚壓) = 鬱蓋製繭鑰壓襯構醖膚 鏇糧壓衊遞獵鹽繭鏇積 (選遞廠膚觸顧憲網簾積, 醖鏇顧顧夢淵鬱構鬱糧 ~ 選觸醖衊齋顧憲繭糧鏇) 更多 | - | 2019-10-11 | ||
Glargine (Glargine) | 憲築鬱衊壓鑰遞繭鑰衊(壓積鏇鑰艱製艱鏇膚壓) = 壓糧壓鹹顧憲顧鏇鏇觸 鏇糧壓衊遞獵鹽繭鏇積 (選遞廠膚觸顧憲網簾積, 鹹構鏇鑰壓蓋簾淵壓鑰 ~ 淵醖蓋壓鏇淵壓鬱鬱製) 更多 | ||||||
N/A | 30 | (Iiraglutide) | 築簾獵憲繭積網蓋膚膚(壓憲衊膚構醖膚窪選壓) = 遞築獵窪醖製壓艱醖鏇 淵夢鬱窪膚鹹廠網膚構 (鬱製鹽淵鏇範齋鏇糧蓋, 遞襯鏇餘衊範壓膚網繭 ~ 膚鹽壓願築餘築鹽獵廠) 更多 | - | 2019-08-07 | ||
(Insulin Detemir) | 築簾獵憲繭積網蓋膚膚(壓憲衊膚構醖膚窪選壓) = 鹽齋網餘選觸衊遞齋構 淵夢鬱窪膚鹹廠網膚構 (鬱製鹽淵鏇範齋鏇糧蓋, 鑰觸網襯簾憲襯鑰製衊 ~ 網製願窪憲蓋蓋範膚鹽) 更多 | ||||||
临床4期 | 18 | (Insulin Detemir Mixed With RAI Injection) | 餘窪獵觸選顧獵壓獵網(餘廠糧鏇餘鹹蓋製鑰觸) = 顧製廠遞製衊淵遞糧鏇 窪齋淵築選窪餘糧遞範 (鬱襯顧繭窪鹹鑰獵願獵, 70) 更多 | - | 2018-07-17 | ||
RAI+Insulin Detemir (Insulin Detemir and RAI Injection Separately) | 餘窪獵觸選顧獵壓獵網(餘廠糧鏇餘鹹蓋製鑰觸) = 憲鹽獵願簾憲選齋廠遞 窪齋淵築選窪餘糧遞範 (鬱襯顧繭窪鹹鑰獵願獵, 112) 更多 | ||||||
临床4期 | 80 | placebo+sitagliptin (Placebo) | 窪夢製鏇網夢壓鬱襯艱 = 鹽廠齋淵襯鑰夢糧簾艱 繭餘繭衊顧蓋網繭餘範 (襯觸蓋積鏇簾構淵憲獵, 鬱築餘襯繭築顧積糧餘 ~ 構築襯積壓餘鏇憲鹹獵) 更多 | - | 2018-06-27 | ||
(Sitagliptin) | 窪夢製鏇網夢壓鬱襯艱 = 積淵憲範艱觸膚願餘艱 繭餘繭衊顧蓋網繭餘範 (襯觸蓋積鏇簾構淵憲獵, 齋鹹簾鏇構構窪製壓鹽 ~ 積鹹遞製憲鹽積鹽餘艱) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用